Election 2026 · Public beta
Independent, source-first accountability
Issue record
Campaign positions remain attributed. Official actions are shown separately, with narrow relationship labels and limits.
Campaign positions
Her campaign says making health care more affordable and accessible for families, seniors and people in rural Maine is one of her priorities. In a July op-ed she backs the INSULIN Act, which would cap insulin at $35 a month for people with private or employer insurance.
His campaign's priorities are to pass Medicare for All and to lower the cost of prescription drugs.
Evidence timeline
official action
In a July op-ed she says she joined three Senate colleagues this spring to introduce the INSULIN Act, and that it passed the Senate health committee by a bipartisan vote of 17 to 5. S. 4189, the INSULIN Act of 2026, was introduced on March 25, 2026 by Jeanne Shaheen for herself, Collins, Raphael Warnock and John Kennedy, with eight more original cosponsors; Collins is named first. The Health, Education, Labor and Pensions Committee ordered it reported with a substitute on July 22, 2026; the committee's own record of that session lists it as agreed to by roll call vote, 17 to 5. It was placed on the Senate calendar on August 7. The reported text keeps a cap of $35 per 30-day supply for private and employer coverage. It has not passed the Senate. Limit: The introduction, the committee's approval and its 17-to-5 tally are on the record, and Congress.gov lists Shaheen as the sponsor, which is what "joined three Senate colleagues" says. The committee's page does not list each senator's vote, but the tally shows both parties voted yes: neither party has 17 seats on the committee (the Senate's roster lists 12 Republicans and 11 Democrats). A bill reported from committee is not law.
official action
In a July op-ed she says that as Appropriations chair she secured a record $200 million for the Special Diabetes Program in this year's funding legislation. Section 6402 of the Consolidated Appropriations Act, 2026, Public Law 119-75, signed February 3, 2026, sets the Special Diabetes Program for Type 1 diabetes at $200,000,000 for fiscal year 2026, against $159,228,188 for 2025 and $155,619,196 for 2024. The program's schedule in the U.S. Code has no year before 2024 above $150,000,000, so $200 million is the largest annual amount it has had. She voted Yea when the Senate passed the act 71 to 29 on January 30 (Roll Call 20). Her own reauthorization bill, S. 2211, introduced in July 2025, had asked for $160,000,000 a year. Limit: The amount, the year and the word record are borne out by the law. "I secured" is a claim about her part in writing it, which no roll call settles: she chaired the committee that produced the year's spending bills and voted for the package, and the enacted amount is larger than her own bill asked for, but the health extensions in it are authorizing provisions that other committees also shaped.
official action
Her campaign lists the Lifespan Respite Care Reauthorization Act, signed in 2026, among the legislation she has authored or co-authored. She introduced S. 830, the Lifespan Respite Care Reauthorization Act of 2025, with Tammy Baldwin on March 4, 2025. The bill went no further than committee, but both of its operative changes became law as section 6506 of the Consolidated Appropriations Act, 2026, signed February 3, 2026: the definition of a family caregiver changes from an unpaid adult to an unpaid individual, in the same words, and the program's funding runs through 2030, for fiscal years 2026 through 2030 rather than the 2025 through 2030 her bill proposed. Limit: What became law is her bill's text inside a larger act, not the stand-alone Act the campaign names, and its funding starts a year later than she proposed. It is the same provision, so the claim holds in substance. The dollar amounts the program receives are set elsewhere and were not compared.
campaign position
His campaign says that in the legislature he fought hard to successfully lower prescription drug prices. In 2019, as Senate President, he sponsored two prescription-drug bills that became law: LD 1499, which created the Maine Prescription Drug Affordability Board, and LD 1272, An Act To Increase Access to Low-cost Prescription Drugs. The Senate accepted the committee's majority report on each 35 to 0 on June 11, 2019, with his Yea vote (Roll Calls 264 and 263), and later enacted both without a recorded vote; the House enacted them 126 to 15 and 138 to 3. Both were signed on June 24, 2019, as Public Law 2019, chapters 471 and 472. In 2021 he sponsored LD 1117, An Act To Prevent Excessive Prices for Prescription Drugs. Both chambers passed it, the Governor vetoed it, and the Senate's override vote, 20 to 14 with his Yea, fell short of the 23 votes needed (Roll Call 506). In 2024 his LD 2114 became a resolve, Resolve 2024, chapter 177, directing the Superintendent of Insurance to collect data on how insurers cover generic drugs and biosimilars and to report to the Legislature. Limit: Sponsorship, his votes and enactment are on the record; the outcome the sentence claims is not.
See something wrong or incomplete? Report it for review.